报价延迟最少15分钟:2025/07/21 06:53 EDT
盘前时段
|
||||
|
1.32 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.32
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-11.05/-1.41
|
|
企业价值
3.16M
|
| 资产负债 |
|
每股账面净值
1.59
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:53 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders. |
